Review of current status of targeted alpha therapy in cancer treatment

Area of Science:

• Oncology
• Nuclear Medicine
• Radiotherapy

Background:

• Targeted alpha therapy (TAT) is an emerging treatment modality for various cancers.
• Preclinical and clinical data suggest TAT's potential for selective tumor cell killing and reduced toxicity.
• This therapy targets tumor cells using alpha-emitting radionuclides.

Purpose of the Study:

• To summarize the developmental trajectory of TAT from research to clinical application.
• To discuss key aspects including properties, production, microdosimetry, and targeting vectors.
• To compare TAT with existing treatments and explore its clinical uses and future impact.

Main Methods:

• Review of preclinical and clinical research data on targeted alpha therapy.
• Analysis of fundamental properties, production pathways, and microdosimetry of alpha emitters.
• Exploration of targeting vectors and comparison with standard cancer treatments.

Main Results:

• TAT demonstrates significant potential for selective tumor cell eradication.
• Minimal toxicity to surrounding healthy tissues is observed.
• Clinical applications and developmental stages from benchtop to commercialization are discussed.

Conclusions:

• Targeted alpha therapy is a rapidly developing field with a high potential for cancer treatment.
• Further research and development are crucial to overcome challenges and realize its full impact on personalized medicine.
• TAT is poised to become an important component of future cancer therapy strategies.